SEC 13F Intelligence

Managers / Q4 2025 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$388M
Q4 2025
Positions
145
Filings on Record
30
2019–present window
Filed
Feb 17, 2026
original filing

Summary

Highvista Strategies LLC reported $388M in U.S.-listed holdings across 145 positions for Q4 2025.

Its largest position, DBC, represents 6.1% of the portfolio.

Compared with Q3 2025, the fund opened 33 new positions and exited 36.

Portfolio Metrics

Turnover
+30.6%
vs prior filed quarter
Top-10 Concentration
+28.1%
share of reported value
Largest Position
+6.1%
Invesco Db Commdy Indx Trck
New / Exited
33 / 36
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 79.5%ADR: 10.4%ETP: 6.1%Other: 4.0%
  • Common Stock · 79.5% · $309M
  • ADR · 10.4% · $41M
  • ETP · 6.1% · $24M
  • Other · 4.0% · $15M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
430TERNS PHARMACEUTICALS INCNEW+175.5K175.5K+$7M$7M
MAZEMAZE THERAPEUTICS INCNEW+170.4K170.4K+$7M$7M
PHARVARIS N VNEW+162.4K162.4K+$5M$5M
STOKSTOKE THERAPEUTICS INCNEW+115.5K115.5K+$4M$4M
CMPSCOMPASS PATHWAYS PLCNEW+498.9K498.9K+$3M$3M
LBRXLB PHARMACEUTICALS INCNEW+140.1K140.1K+$3M$3M
PALIPALISADE BIO INCNEW+1.30M1.30M+$3M$3M
T7DTRANSDIGM GROUP INCNEW+2.2K2.2K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2025

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DBCINVESCO DB COMMDY INDX TRCKhistory →UNIT6.09%$24M1.06M
2GPCRSTRUCTURE THERAPEUTICS INChistory →SPONSORED ADS3.46%$13M193.0K
3COGTCOGENT BIOSCIENCES INChistory →COM3.08%$12M336.7K
4VRDNVIRIDIAN THERAPEUTICS INChistory →COM2.99%$12M372.5K
5ABVXABIVAX SAhistory →SPONSORED ADS2.51%$10M72.2K
6RVMDREVOLUTION MEDICINES INChistory →COM2.47%$10M120.2K
7PRAXPRAXIS PRECISION MEDICINES Ihistory →COM NEW1.96%$8M25.8K
8NUVLNUVALENT INChistory →COM1.90%$7M73.3K
9CYTKCYTOKINETICS INChistory →COM NEW1.87%$7M114.6K
10430TERNS PHARMACEUTICALS INChistory →COM1.83%$7M175.5K
11MAZEMAZE THERAPEUTICS INChistory →COM1.82%$7M170.4K
12IM8NINSMED INChistory →COM PAR $.011.77%$7M39.4K
13APGEAPOGEE THERAPEUTICS INChistory →COM1.73%$7M89.2K
14PTGXPROTAGONIST THERAPEUTICS INChistory →COM1.65%$6M73.5K
15SLNOEURSOLENO THERAPEUTICS INChistory →COM1.61%$6M135.1K
16SYRESPYRE THERAPEUTICS INChistory →COM NEW1.59%$6M188.2K
17BBIOBRIDGEBIO PHARMA INChistory →COM1.58%$6M80.2K
18OLMAOLEMA PHARMACEUTICALS INChistory →COM1.55%$6M241.5K
19IMVTIMMUNOVANT INChistory →COM1.45%$6M221.9K
20LQDALIQUIDIA CORPORATIONhistory →COM NEW1.39%$5M156.0K
21PCVXVAXCYTE INChistory →COM1.36%$5M114.0K
22CDTXCIDARA THERAPEUTICS INChistory →COM NEW1.30%$5M22.9K
23ACLXGBXARCELLX INChistory →COMMON STOCK1.26%$5M75.0K
24RLAYRELAY THERAPEUTICS INChistory →COM1.19%$5M545.1K
25RYTMRHYTHM PHARMACEUTICALS INChistory →COM1.18%$5M42.9K
26MLYSMINERALYS THERAPEUTICS INChistory →COM1.16%$5M124.5K
27PHARVARIS N VCOM1.16%$5M162.4K
28TARSTARSUS PHARMACEUTICALS INChistory →COM1.13%$4M53.6K
29EWTXEDGEWISE THERAPEUTICS INChistory →COM1.09%$4M171.1K
30OCULOCULAR THERAPEUTIX INChistory →COM1.08%$4M344.1K
31AGIOAGIOS PHARMACEUTICALS INChistory →COM1.04%$4M147.7K
32AMZNAMAZON COM INChistory →COM1.03%$4M17.4K
33APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.98%$4M150.8K
34GHGUARDANT HEALTH INCCOM0.97%$4M36.8K
35STOKSTOKE THERAPEUTICS INCCOM0.94%$4M115.5K
36CMPSCOMPASS PATHWAYS PLCSPONSORED ADS0.89%$3M498.9K
37MSFTMICROSOFT CORPCOM0.81%$3M6.5K
38LBRXLB PHARMACEUTICALS INCCOM SHS0.80%$3M140.1K
39PALIPALISADE BIO INCCOM0.79%$3M1.30M
40GH RESEARCH PLCORDINARY SHARES0.79%$3M240.5K
41ARGXARGENX SESPONSORED ADR0.78%$3M3.6K
42X0M1XOMA ROYALTY CORPORATIONCOM NEW0.77%$3M112.9K
43T7DTRANSDIGM GROUP INCCOM0.74%$3M2.2K
44RNAGBPAVIDITY BIOSCIENCES INCCOM0.74%$3M40.0K
45AMLXAMYLYX PHARMACEUTICALS INCCOM0.74%$3M238.8K
46BBOTBRIDGEBIO ONCOLOGY THERAPEUTCOM NEW0.74%$3M229.3K
47NVDANVIDIA CORPORATIONCOM0.68%$3M14.2K
48CRMSALESFORCE INCCOM0.59%$2M8.6K
49VVISA INCCOM CL A0.57%$2M6.3K
50SEPNSEPTERNA INCCOM0.56%$2M78.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • HighVista Private Capital Management LLC

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.